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Background: 
Selective inhibitors of cyclooxygenase (COX)-2 are commonly used analgesics in various pain conditions. 
Although their actions are largely thought to be mediated by the blockade of prostaglandin (PG) biosynthesis, 
evidences suggesting endogenous opioid peptide link in spinal antinociception of COX inhibitor have been 
reported. We investigated the roles of opioid receptor subtypes in the spinal antinociception of selective COX-2 
inhibitor.
Methods: 
To examine the antinociception of a selective COX-2 inhibitor, DUP-697 was delivered through an intrathecal 
catheter, 10 minutes before the formalin test in male Sprague-Dawley rats. Then, the effect of intrathecal 
pretreatment with CTOP , naltrindole and GNTI, which are μ, δ and κ opioid receptor antagonist, respectively, 
on the analgesia induced by DUP-697 was assessed.
Results: 
Intrathecal DUP-697 reduced the flinching response evoked by formalin injection during phase 1 and 2. 
Naltrindole and GNTI attenuated the antinociceptive effect of intrathecal DUP-697 during both phases of the 
formalin test. CTOP reversed the antinociception of DUP-697 during phase 2, but not during phase 1.
Conclusions: 
Intrathecal DUP-697, a selective COX-2 inhibitor, effectively relieved inflammatory pain in rats. The δ and 
κ opioid receptors are involved in the activity of COX-2 inhibitor on the facilitated state as well as acute pain 
at the spinal level, whereas the μ  opioid receptor is related only to facilitated pain. (Korean  J  Pain  2010; 
23:  236-241)
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Table 1. Pharmacological Characteristics of the Experimental Drugs
Subtype affinity Selectivity ratio
DUP-697
IC50*  (μM)
COX-1 COX-2
0.5 0.006 50 (COX-1/-2)
Opioid receptor 
antagonists
Ki
† (nM)
μ-receptor δ-receptor κ-receptor
CTOP
Naltrindole
GNTI
0.18
64
37
＞ 1,000
0.02
70
＞ 1,000
66
0.18
＞ 5,000 (δ/μ)
  3,200 (μ/δ)
    206 (μ/κ)
> 5,000 (κ/μ)
   3,300 (κ/δ)
     389 (δ/κ)
*The half maximal inhibitory concentration, 
†The inhibition constant.
INTRODUCTION
    As a consequence of the rapidly aging population and 
the increasing prevalence of degenerative arthritis, there 
is a great demand on the drugs that manage inflammatory 
p a i n .  A c c o r d i n g l y ,  s e l e c t i v e  i n h i b i t o r s  o f  c y c l o o x y g e n a s e 
(COX)-2 are one of the most widely used analgesics and 
i t s  a c t i o n s  a r e  w e l l  e s t a b l i s h e d  t o  b e  m e d i a t e d  b y  t h e 
blockade of prostaglandin biosynthesis. However, several 
lines of evidence suggest that mechanisms of COX-2 in-
hibitor beyond the inhibition of COX and PG biosynthesis 
might also play an important role in their antinociception. 
Herrero and Headley. [1] reported that the opioid antago-
nist  naloxone  fully  reversed  or  prevented  the  anti-
nociception by flunixin, a non-steroidal anti-inflammatory 
drugs, in rats with carrageenan-induced inflammation of 
the hindpaw. Ibuprofen [2] and ketorolac [3] raised blood 
levels  of  endogenous  opioids  in  human  and  rats, 
respectively. Pre-treatment with naltrexone diminished the 
a n a l g e s i c  e f f e c t s  o f  a  C O X - 2  i n h i b i t o r ,  a n d  i t s  a n t i -
nociception was abolished in rats made tolerant to the an-
algesic effects of morphine [4]. Taken together, these data 
indicate that there is a link between the opioid system and 
COX-2 inhibitor antinociception. However, the sites and 
mechanisms of any such connection are not yet clear.
    The aim of this study was to clarify the role of opioid 
receptor subtypes on the effect of COX-2 inhibitor at the 
spinal level. Thus, μ, δ and κ opioid receptor antagonists 
were intrathecally administered to investigate the ability of 
opioid receptor subtype antagonists to reverse the anti-
nociception induced by COX-2 inhibitor in the formalin test 
which shows an early phase of acute nociceptive response 
followed by a late phase response being related to more 
complex inflammatory reactions.
MATERIALS  AND  METHODS
    All of the proced ures were carried out with the appro-
val of the Institutional Animal Care Committee, Research 
Institute  of  Medical  Science.  Male  Sprague-Dawley  rats 
weighing 250-300 g were used in these experiments. The 
rats were housed in a vivarium maintained at 20-23
oC with 
12-h light/dark cycle and were given food and water ad 
libitum. A polyethylene tube (PE-10) was catheterized and 
i n s e r t e d  i n t o  t h e  s u b a r a c h n o i d  s p a c e  i n  s e v o f l u r a n e -  
anesthetized rats as described previously [5,6]. The rats 
were closely  monitored  and,  if motor abnormalities ap-
peared,  they  were  euthanized  through  a  volatile  anes-
thetics overdose. Normal rats were kept in individual cages 
and a period of not less than 5 days was allowed for each 
rat to recover from intrathecal catheterization. Rats show-
ing apparently normal behavior and weight gain were as-
signed to the experiment.
    The f ollowing drugs were used in this study: DUP-697 
(5-Bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phe-
nyl]-thiophene,), CTOP (d-Phe-Cys-Tyr-d-Trp-Orn-Yhr- 
NH2,),  naltrindole  (17-(cyclopropylmethyl)-6,7-dehydro- 
4,5α-epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphian 
hydrochloride,) and GNTI (5'-guanidinyl-17-(cyclopropyl-
methyl)-6,7-dehydro-4,5α-epoxy-3,14-dihydroxy- 
6,7-2',3'-indolomorphian dihydrochloride, Tocris Cookson, 
Bristol, UK). Pharmacological characteristics of the above 
e x p e r i m e n t a l  d r u g s  a r e  p r e s e n t e d  i n  T a b l e  1  [ 7 - 9 ] .  A l l  
drugs were dissolved in dimethylsulfoxide (DMSO) and in-238 Korean J Pain Vol. 23, No. 4, 2010
Fig. 1. Time course (A) and dose-response curves of 
intrathecal DUP-697 on flinching during phase 1 (B) and 
phase 2 (C) in the formalin test. DUP-697 was admini-
stered 10 min before the formalin injection. Data are 
presented as the number of flinches or the percentage of 
control. Each line represents means ± S.E.M. of 5−8 
rats. Compared with control, *P  ＜ 0.05, 
†P ＜ 0.005, 
‡P  ＜ 0.001.
trathecally administered using a hand-driven, gear-oper-
ated syringe in a volume of 10 μl solution followed by an 
additional 10 μl of saline to flush the catheter.
    On experiment days, rats were placed in a restraining 
cylinder and held for 20 min for adaptation. To investigate 
the effect of COX-2 inhibitor in the formalin test, rats 
were treated with vehicle or DUP-697 (10, 30, 100, 300 
μg ) ,  g i v e n  1 0  m i n  b e f o r e  t h e  f o r m a l i n  t e s t .  D o s e s  o f  
DUP-697 were determined by the maximum solubility and 
for  approximately equal  spacing  on  the  log-scale.  Rats 
were then pretreated with several opioid receptor antago-
nists in order to determine which subtypes of opioid re-
ceptor affected DUP-697 activity. These antagonists were 
administered intrathecally 10min before the delivery of in-
trathecal DUP-697 (300 μg). The formalin test was per-
formed 10 min later. Three antagonists were selected on 
the basis of their selectivity on the receptor (Table 1) [7,9]. 
D o s e s  o f  t h e  o p i o i d  r e c e p t o r  a n t a g o n i s t s  w e r e  c h o s e n  
based on previous experiment [10], in which the maximum 
dosage that did not affect the control formalin response 
o r  c a u s e  s i d e  e f f e c t s  s u c h  a s  m o t o r  i m p a i r m e n t  w a s  
determined. The opioid receptor antagonists used were as 
follows:  μ  opioid  receptor  antagonist,  CTOP  (15  μg);  δ 
opioid receptor antagonist, naltrindole (10 μg); κ opioid re-
ceptor antagonist, GNTI (50 μg). Animals were tested only 
once. In total, 55 rats were tested in this study and the 
number of rats per group was 5-8.
    F or the formalin test, 50 μl of 5% formalin was in-
jected subcutaneously into the plantar surface of the rat 
hindpaw.  The  number  of  flinches  was  counted  for  the 
1-min periods at 1 and 5 min after the formalin injection, 
and every 5 min thereafter. Rats were observed for a total 
period of 60 min. Observed responses were divided into 
phase 1 (0-9 min) and phase 2 (10-60 min) of the formalin 
test. The researcher that tested the drugs was blind to the 
drug given to each animal. Data are expressed as means C H  C h o i ,  e t  a l  /  O p i o i d  R e c e p t o r  S u b t y p e  a n d  C O X 2  I n h i b i t o r 239
Fig. 2. The effects of intrathecal CTOP (15 μg), naltrindole (10 μg) and GNTI (50 μg) on the antinociception by intrathecal
DUP-697 (300 μg) during phase 1 (A) and phase 2 (B) in the formalin test. CTOP, naltrindole and GNTI were administered
10min before the delivery of DUP-697, and then the formalin test was done 10 min later. Both of naltrindole and GNTI
reversed the effect of DUP-697 during phase 1 and phase 2 in the formalin test. CTOP antagonized the antinociception
of DUP-697 during phase 2, but not during phase 1. Data are presented as the percentage of control. Each bar represents
means ± S.E.M. of 5−8 rats. Compared with DUP-697, *P  ＜ 0.05.
± SEM. Time response data or dose-response data are 
shown either as the number of flinches or the percentage 
o f  c o n t r o l  i n  t w o  p h a s e s .  C o n t r o l  s t u d y  w a s  d o n e  w i t h 
DMSO, and the flinching number of the experimental group 
was converted to a percentage of control as follows:
            Total flinching number with drug in phase 1(2)
% of con trol =                                          × 100%
              T otal flinching n um ber of con trol in phase 1(2)
    Dose-response data was analyzed using one-way 
a n a l y s i s  o f  v a r i a n c e  ( A N O V A )  w i t h  S c h e f f e  post  hoc 
analysis.  Comparison  of  antagonism  for  the  effect  of 
DUP-697 was analyzed by unpaired t-test. A P  value ＜ 
0.05 was considered statistically significant.
RESULTS
    Subcutaneous injection of f ormalin in to the pa w e voked 
a biphasic pattern of flinching, with an early (phase 1) re-
sponse lasting 5-10 min, and after a quiescent interval of 
5-10 min, a subsequent late (phase 2) response up to 60 
min. Fig. 1 shows the time course and dose-response data 
of intrathecal DUP-697, administered 10 min before for-
malin injection, for the formalin test. In the control group, 
total flinching number was (mean ± SEM) 28 ± 3 and 228 
±  1 5 ,  d u r i n g  p h a s e  1  a n d  2 ,  r e s p e c t i v e l y .  I n t r a t h e c a l  
DUP-697  reduced  flinching  response  to  35-50%  of  the 
control group during phase 1 of the formalin test, but the 
extent of change was not statistically different over the 
range of administered dosage (Fig. 1B). During phase 2, 
DUP-697 suppressed the flinching response up to 48% of 
control in a dose-dependent manner (Fig. 1C).
    When CTOP was delivered intrathecally, 10 min before 
DUP-697  administration,  total  flinching  number  during 
phase 1 and 2 was 57% (P ＞ 0.05) and 79% (P ＜ 0.05) 
of the control value, respectively. Thus, pretreatment with 
μ o p i o i d  r e c e p t o r  a n t a g o n i s t  C T O P  r e v e r s e d  t h e  a n t i -
n o c i c e p t i v e  e f f e c t  o f  D U P - 6 9 7  d u r i n g  p h a s e  2 ,  b u t  n o t 
during phase 1, of the formalin test (Fig. 2). Total flinching 
number of the naltrindole-pretreated group during phase 
1 and 2 was 73% and 74%, respectively (P ＜ 0.05), and 
that of the GNTI-pretreated group was 69% and 76% of 
the  control  value,  respectively  (P  ＜  0.05)  (Fig.  2). 
Therefore, both δ and κ opioid receptor antagonists re-
versed the effects of DUP-697 in both phases.
DISCUSSION
    It is generally thought that distinct mechanisms un-
derlie the two phases of behavioral response in the formal-240 Korean J Pain Vol. 23, No. 4, 2010
in test. The phase 1 response is believed to represent a 
direct activation of sensory C fibers of primary afferent 
by formalin, thus phase 1 of the formalin test reflects acute 
pain. In contrast, the phase 2 response may result from 
the activation of wide dynamic range neurons with a con-
tinuously low level of activity in the primary afferent, thus 
representing a facilitated state [11]. 
    In this study, intrathecal DUP-697 reduced the flinch-
ing  response  evoked  by  formalin  injection  during  both 
phases. This finding suggests that this selective COX-2 
inhibitor possesses a central mechanism of action, which 
is consistent with a previous report [12]. Moreover, pre-
treatment with intrathecal μ, δ and κ opioid receptor an-
tagonists  attenutated  the  effect  of  DUP-697,  indicating 
that the endogenous opioid system mediate spinal anti-
nociception of CO X-2 inhibitor.
    The involvement of the endogenous opioid system in 
the COX inhibitor analgesia has already been documented 
in other reports with various human and animal models. 
Troullos et al. [2] reported that ibuprofen enhances pitui-
tary release of beta-endorphin by corticotroph cells in re-
sponse to surgical stress in humans. In the mice model of 
n o c i c e p t i o n ,  i n t r a p e r i t o n e a l  a d m i n i s t r a t i o n  o f  n a l o x o n e  
significantly decreased the analgesic activity of ketorolac, 
suggesting that the opioid system might play a role in the 
COX inhibitor analgesia [13]. Recently, in a study by França 
et al. [4] selective inhibitors of CO X-2 raised the noci-
ceptive threshold above the normal non-inflamed level in 
a rat carrageenan model, and pre-treatment with naltrex-
one, an opioid receptor antagonist, abolished this effects. 
Moreover, in rats made tolerant to the anti-nociceptive ef-
fects of morphine, all antinociceptive effects of the COX-2 
i n h i b i t o r  w e r e  a l s o  a b o l i s h e d  [ 4 ] .  T a k e n  t o g e t h e r ,  t h e s e 
data indicate that there is a significant interaction between 
the  opioid  system  and  COX-2  inhibitor  antinociception. 
However, until now, the roles of opioid receptor subtypes 
on the effect of COX-2 inhibitor at the spinal level were 
not determined.
    In the current study, intrathecal CTOP, naltrindole, 
and GNTI attenuated the antinociceptive effect of intra-
thecal DUP-697 during both phases of the formalin test. 
However, the antinociception observed during phase 1 was 
antagonized by naltrindole and GNTI, but not CTOP. These 
observations suggest that δ and κ opioid receptors are in-
volved in the activity of COX-2 inhibitor on the facilitated 
state as well as acute pain at the spinal level, whereas the 
μ opioid receptor is not related to the action of COX-2 in-
hibitors on acute pain.
   The mechanism underlying opioid-mediated CO X-2 in-
hibitor antinociception has not been clearly defined. Some 
COX inhibitors, such as paracetamol [14], have been re-
ported to be able to bind to opioid receptors. However, it 
is unlikely that the COX-2 inhibitor used in this study, act-
ed directly on the opioid receptor as an agonist because 
the nociceptive thresholds of the contralateral paw in in-
flamed rats were not affected, in contrast to the effects 
of the opioid receptor agonist, morphine [15]. In addition, 
the small effects the COX inhibitor had in rats with normal 
p a w s ,  w e r e  n o t  r e v e r s e d  b y  a  d o s e  o f  n a l o x o n e  h i g h  
enough to block actions mediated at both the  μ an d  κ 
opioid receptors [1,16]. A more likely explanation for the 
opioid-COX link would be the release of endogenous opioid 
peptides by the COX inhibitor, which is consistent with the 
increase of blood levels of endogenous opioids after COX 
inhibitor administration [2,3] and also compatible with the 
finding that prostaglandins can block endogenous opioid- 
mediated analgesia [17]. This possibility was further sup-
ported by the potentiation of celecoxib’s effects by bes-
tatin, a compound known to inhibit metabolism and con-
sequent inactivation of endogenous opioid peptides [15]. On 
the other hand, the hyperalgesia, as a consequence of pe-
ripheral inflammation induced by a variety of agents, is 
associated with increased dynorphin expression [18-20], 
and opioid receptor antagonists reversed the decrease in 
dynorphin level induced by paracetamol [21]. Thus, some 
COX inhibitors may exert their antinociceptive effect also 
through the opioidergic system modulating dynorphin re-
lease in the central nervous system [21]. However, mecha-
nisms of the unilateral analgesia, observed in the endoge-
nous opioid-mediated CO X inhibitor an tinociception, re-
mains to be further investigated, which may possibly be 
associated  with  inflammation-induced  change  in  opioid 
receptor binding and G-protein coupling [22]. In addition, 
the differential role of the endogenous opioid system medi-
ating COX inhibitor analgesia in the acute and facilitated 
states should be explored in future studies.
    In conclusion, intrathecal administration of a CO X-2 
inhibitor  decreased  inflammatory  pain,  and  its  anti-
n oci c e p ti v e a c ti o n w as m ed ia ted  b y δ an d κ o pi oi d  r e-
ceptors  in  formalin-induced  acute  and  facilitated  pain. 
Additionally, the μ opioid receptor was involved in COX-2 
inhibitor antinociception in the facilitated state.C H  C h o i ,  e t  a l  /  O p i o i d  R e c e p t o r  S u b t y p e  a n d  C O X 2  I n h i b i t o r 241
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